Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Mezigdomide in Hepatic Impairment
NCT05707390Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of mezigdomide in multiple myeloma (MM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration up to 6 days, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration up to 6 days and 1 more. Started Feb 2023; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05707390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707390.